A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
A February 2026 review analyzes strategies for kidney-targeted drug delivery systems, examining renal targeting mechanisms and nanocarrier platforms. The review highlights how functionalized nanoparticles can achieve enhanced renal specificity while addressing remaining translational challenges in the field.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
New research suggests GLP-1 medications like Ozempic and Wegovy could help protect the heart after a heart attack by reopening tiny blood vessels that remain blocked even after major arteries are cleared during emergency treatment.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
University of Alberta researchers identified GlpG protease as a new drug target for treating antibiotic-resistant E. coli, which causes 250,000 UTI deaths annually. Inhibiting the protease prevented bacterial adhesion and biofilm formation in laboratory tests.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
China Medical System Holdings partnered with Insilico Medicine on AI-powered drug discovery in early February 2026 and received Chinese regulatory approval to begin human trials for complement factor B inhibitor CMS-D017.
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600450 |
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive |
NOT_YET_RECRUITING | PHASE1 |
| NCT07597005 |
Red Propolis Supplementation as a Strategy in Chronic Kidney Disease |
RECRUITING | NA |
| NCT07595952 |
The Adaptive Platform Trial for Kidney Disease |
NOT_YET_RECRUITING | NA |
| NCT07572890 |
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study |
RECRUITING | PHASE1 |
| NCT07542964 |
Transgender Analysis of Nephrological Studies Focused on Renal Metrics |
NOT_YET_RECRUITING | |
| NCT07492511 |
Renal and Hepatic Abnormal Doppler Patterns in Trauma |
RECRUITING | |
| NCT07485075 |
Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial |
RECRUITING | NA |
| NCT07465926 |
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3 |
COMPLETED | |
| NCT07431931 |
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria |
NOT_YET_RECRUITING | NA |
| NCT07426380 |
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function |
RECRUITING | PHASE1 |
